Generation Of A Naïve Human Scfv Antibody Library For The Production Of Human Monoclonal Antibodies By Using Phage Display Technology by Lim , Bee Nar
i 
 
GENERATION OF A NAÏVE HUMAN scFv 
ANTIBODY LIBRARY FOR THE PRODUCTION 
OF HUMAN MONOCLONAL ANTIBODIES BY 
USING PHAGE DISPLAY TECHNOLOGY 
 
by 
 
LIM BEE NAR 
 
 
Thesis submitted in fulfilment of the requirements 
for the degree of Master of Science 
 
 
 
SEPTEMBER 2015  
ii 
 
ACKNOWLEDGEMENTS 
 
I would like to express my sincere gratitude and appreciation to the following 
individuals for their assistances and encouragements throughout my study. 
First and foremost, I would like to thank my supervisor, Dr. Lim Theam Soon 
for his enormous support, guidance and advice. Thank you for sharing knowledge as 
well as the time spent for the completion of this project. Without your patience and 
criticisms, this project would not have been the same. 
I would like to send my special thanks to my co-supervisor, Prof. Dato’ Dr. 
Asma Ismail and Dr. Choong Yee Siew. Their assistances and suggestions for the 
project throughout my study are highly appreciated.  
I would like to extend my thanks to all my labmates and staff members in the 
Institute For Research In Molecular Medicine for their help and support as well. I 
would also like to acknowledge the Ministry of Education MyMasters for awarding 
me scholarship and supporting me by financial means. 
Last but not least, I would like to show my deepest gratitude and I am 
especially indebted to my parents for their understanding and moral support in the 
whole duration of this study. Thank you. 
 
 
 
iii 
 
TABLE OF CONTENTS 
          
               PAGE 
Acknowledgements                                                                                                       ii 
Table of Contents                                                                                                         iii 
List of Tables                                                                                                               xi 
List of Figures                                                                                                             xii 
List of Abbreviations                                                                                                  xv 
List of Symbols                                                                                                        xviii 
List of Publications                                                                                                xix 
Abstrak                                                                                                                      xxii 
Abstract                                                                                                                    xxiv 
CHAPTER 1 – INTRODUCTION                                                                           1 
1.1 Research background                                                                                        1 
1.2 Literature review                                                                                        2 
1.2.1 Immune system                                                                            2 
1.2.2 Antibody and its classes                                                                        3 
1.2.3 The structure of antibody                                                                      6 
1.2.4 Recombinant antibody                                                                7 
1.2.5 Diversity of antibody                                                                            9 
1.2.6 Antibody library                                                                            9 
iv 
 
1.2.6.1 Naive library                                                                          11 
1.2.6.2 Immunized library                                                              12 
1.2.6.3 Synthetic library                                                              12 
1.2.7 Phage display                                                                                      13 
1.2.7.1 Phage biology                                                                          14 
1.2.7.2 Antibody phage display                                                  15 
1.2.8 Biopanning                                                                                      18 
1.2.9 Antibody mutagenesis                                                              20 
1.3 Rationale of study                                                                                      22 
1.4 Objectives                                                                                                  24 
CHAPTER 2 – MATERIALS AND METHODS                                                  25 
2.1  Reagent preparation                                                                                      25 
2.2 Molecular biology based methods                                                              27 
 2.2.1 Purification of plasmid                                                              27 
 2.2.2 Extraction of DNA by gel electrophoresis                                      28 
 2.2.3 Ethanol precipitation of DNA                                                             28 
 2.2.4 Determination of DNA concentration                                                 28 
 2.2.5 Restriction enzyme digestion of DNA                                                29 
 2.2.6 Dephosphorylation of linearized vectors                                            29 
 2.2.7 Ligation of DNA into vector                                                              29 
 2.2.8 Preparation of electrocompetent cells                                                  30 
v 
 
 2.2.9 Electroporation                                                                          30 
 2.2.10 Amplification by PCR method                                                            31 
2.3 RNA preparation methods                                                                          31 
 2.3.1 Separation of peripheral blood mononuclear cell and  
   extraction of RNA                                                                          31 
 2.3.2 Evaluation of RNA sample                                                               32 
 2.3.3 Reverse transcription PCR                                                              32 
2.4 Protein based methods                                                                                      33 
 2.4.1 Expression of antigen protein                                                              34 
 2.4.2 Extraction of periplasmic protein                                                   34 
 2.4.3 Extraction of cytoplasmic protein                                                       34 
 2.4.4 His-tag protein purification using Ni-NTA column                          34 
 2.4.5 Preparation of SDS-PAGE                                                              35 
 2.4.6 Staining and destaining of polyacrylamide gel                                   35 
 2.4.7 Western blotting                                                                                  35 
2.5 Phage display based methods                                                                          36 
 2.5.1 Preparation of helper phage plaque                                                   36 
 2.5.2 Packaging and precipitation of helper phage                                      37 
 2.5.3 Titration of helper phage particle                                                  38 
vi 
 
 2.5.4 Preparation of antibody phage library                                                 38 
2.6 Semi-automated antibody phage display panning methods                          39 
 2.6.1 Antigen protein conjugation on magnetic nanoparticle              39 
 2.6.2 Semi-automated biopanning method                                                  39 
2.7 Conventional microplate antibody phage displa panning methods              41 
 2.7.1 Immobilization of antigen protein on microplate                          41 
 2.7.2 Microplate biopanning method                                                  41 
2.8 Polyclonal and monoclonal antibody phage ELISA and screening           
 based methods                                                                                                  42 
 2.8.1 Polyclonal antibody phage ELISA                                                  42 
 2.8.2 Phage particle packaging and screening for monoclonal  
   antibodies                                                                                      43 
 2.8.3 ELISA of phage and soluble monoclonal antibodies                 44 
2.9 Single-stranded DNA mutagenesis based methods                                      45 
 2.9.1 Generation of single-stranded DNA                                                  45 
 2.9.2 Evaluation of single-stranded DNA                                                  45 
 2.9.3 Annealing of two single-stranded DNA                                      46 
 2.9.4 Filling in reaction with Klenow fragment                                           46 
 2.9.5 Determination of library diversity using DiStRO method              46 
vii 
 
2.10   E. coli cell genotypes                                                                                      47 
2.11   Plasmids                                                                                                  47 
CHAPTER 3 – RESULTS                                                                                      49 
3.1 Generation of antibody V-gene                                                               49 
 3.1.1  Blood collection from donors                                                              49 
 3.1.2 RNA extraction and reverse transcription                                          51 
3.2 Construction of naive scFv antibody library by PCR Assembly                       54 
 3.2.1 First heavy chain and light chain amplification                          54 
 3.2.2 VH elongation with linker sequence using PCR                          58 
 3.2.3 VL amplification                                                                          60 
 3.2.4 scFv PCR assembly                                                                          60 
 3.2.5 Cloning of scFv into phagemid vector                                      63 
 3.2.6 Validation of naive scFv antibody library                                      63 
3.3 scFv antibody library construction with two step cloning method              65 
 3.3.1 First cloning step with VL                                                              65 
 3.3.2 Validation of naive VL antibody library                                      67 
 3.3.3 Second cloning step with VH-linker                                                  69 
 3.3.4 Validation of naive scFv antibody library                                      69 
3.4 Protein expression and immobilization on magnetic nanoparticles              71 
viii 
 
 3.4.1 Protein expression of ubiquitin (Ub), hemolysin E (hlyE) 
    and HIV matrix protein p17 (MAp17)                                      71 
 3.4.2 Antigen conjugation on magnetic nanoparticles                          74 
3.5 ELISA of polyclonal antibody phage against antigens                                      76 
 3.5.1 Polyclonal phage ELISA against ubiquitin, MAp17 and  
   hemolysin E                                                                                      76 
3.6 ELISA of monoclonal antibody phage against antigens                          79 
 3.6.1 Monoclonal phage ELISA against ubiquitin, MAp17 and  
   hlyE                                                                                                  79 
3.7 V-gene analysis for monoclonal scFv antibody                                      81 
3.8 Expression of antibody as soluble protein                                                  83 
3.9 Soluble scFv antibody protein ELISA against ubiquitin, Map17  
 and hlyE protein                                                                                      85 
3.10 Western blot analysis                                                                                      87 
3.11 Nucleotide-based diversity using lambda exonuclease                                      90 
 3.11.1 Generation of single-stranded DNA (ssDNA)                          90 
 3.11.2 Klenow fragment filling in                                                              94 
 3.11.3 Diversity of library by DiStRO assay                                                  96 
CHAPTER 4 – DICUSSION                                                                                      98 
ix 
 
4.1 Preparation of antibody V-gene repertoires                                                   98 
4.2 Generation of naive antibody library                                                            100 
4.3 Characteristic of scFv phagemid vector design                                    102 
4.4 Expression of soluble antibody protein                                                103 
4.5 Biopanning for antibody selection                                                            104 
4.6 Enrichment of polyclonal and monoclonal antibody against antigen           105 
4.7 Monoclonal antibody V-gene repertoire analysis                                    107 
4.8 Evaluation of soluble antibody protein                                                108 
4.9 Antibody affinity maturation                                                                        109 
CHAPTER 5 – CONCLUSION                                                                        112 
5.1  Conclusion                                                                                                112 
5.2  Limitations and suggestions                                                                        114 
REFERENCES                                                                                                116 
APPENDICES                                                                                                126 
Appendix A Questionnaire for blood collection                                                126 
Appendix B Human ethics patient form                                                            130 
Appendix C Primer used for antibody V-gene amplification                        135 
Appendix D V-gene PCR amplification for antibody fragment, VH-CH  
and VL-CL (750 bp) at 55 
o
C                                                            137 
x 
 
Appendix E V-gene PCR amplification for antibody fragment, VH-CH 
 and VL-CL (750 bp) at 62 
o
C                                                138 
Appendix F Complete amplification of scFv format at 750 bp using  
scFv PCR assembly                                                                        139 
Appendix G Round 1 semi-automated biopanning using KingFisher Flex           140 
Appendix H Round 2 semi-automated biopanning using KingFisher Flex           141 
Appendix I Round 3 semi-automated biopanning using KingFisher Flex           143 
 
 
 
 
 
 
 
 
 
 
 
 
xi 
 
LIST OF TABLES 
                        PAGE 
Table 3.1 RIN value for donors                                                                          53 
Table 3.2 Primers used to amplify V-genes and its best annealing  
temperature                                                                                      55 
Table 3.3  V-gene analysis of the monoclonal antibody                                      82 
  
xii 
 
LIST OF FIGURES 
                                                    PAGE 
Figure 1.1 Structure of an antibody molecule                                                        5 
Figure 1.2 Different formats of antibodies                                                             8 
Figure 1.3 Schematic diagram of antibody library generation                             10 
Figure 1.4 Structure of phage particle                                                              17 
Figure 1.5 Schematic diagram of biopanning                                                  19 
Figure 1.6 Methods of antibody mutagenesis                                                  21 
Figure 2.1 Map of plasmid vectors                                                              48  
Figure 3.1 Isolation of peripheral blood mononuclear cells                          50 
Figure 3.2 Bioanalyzer electropherogram                                                            52 
Figure 3.3 Agarose gel of V-gene sequence        56 
Figure 3.4 Agarose gel of V-gene sequence         57 
Figure 3.5 Agarose gel of antibody gene amplification                59 
Figure 3.6 Agarose gel of complete scFv fragment optimization                        61 
Figure 3.7 Agarose gel of complete scFv fragment amplification              62 
Figure 3.8 Estimation of library size                                                              64 
Figure 3.9 Percentage of insert                                                                          64 
Figure 3.10 Digestion of antibody gene                    66 
xiii 
 
Figure 3.11 Estimation of library size                                                              68 
Figure 3.12 Percentage of insert                                                                          68 
Figure 3.13 Estimation of library size                                                              70 
Figure 3.14 Percentage of insert                                                               70 
Figure 3.15 Coomassie stained SDS-PAGE gel                                                  73 
Figure 3.16 Coomassie stained SDS-PAGE gel                                                     73 
Figure 3.17 Coomassie stained SDS-PAGE gel                 75 
Figure 3.18 ELISA result of biopanning                                                              78 
Figure 3.19 ELISA result of antibody selection                  80 
Figure 3.20 Coomassie stained SDS-PAGE gel                                       84 
Figure 3.21 ELISA result of soluble antibody protein                                      86 
Figure 3.22 ELISA result of soluble antibody protein                                      86 
Figure 3.23 Western blot detection of soluble antibody protein  
against target antigen                                  89 
Figure 3.24 Western blot detection of soluble antibody protein  
against target antigen                       89 
Figure 3.25 Optimization of lambda exonuclease digestion                                  91 
Figure 3.26 Single-stranded DNA detection with AGE gel                          93 
Figure 3.27 Single-stranded DNA detection with fluorescence  
xiv 
 
  reading                                                                                                 93 
Figure 3.28 Optimization of Klenow fragment                                                  95 
Figure 3.29 Optimization of new hybrid annealing protocol                          95 
Figure 3.30 Optimization of new hybrid annealing protocol                          95 
Figure 3.31 Estimation of antibody diversity                                                   97 
 
 
 
 
 
 
 
 
 
 
 
 
xv 
 
LIST OF ABBREVIATIONS 
amp  ampicillin 
bp  base pair 
CH  constant heavy 
CL  constant light 
CDR  complementary determining region 
cDNA  complementary DNA 
dNTP  deoxynucleotide triphosphate 
DNA  deoxyribonucleic acid 
dH2O  distilled water 
DiStRO diversity standard of random oligonucleotide 
dsDNA double stranded DNA 
ELISA  enzyme linked immunosorbent assay 
E. coli  Escherichia coli 
EtBr  ethidium bromide 
glu  glucose 
His-tag histidine tag 
hlyE  hemolysin E 
HRP  horseradish peroxidase 
xvi 
 
hr  hour 
HIV  human immunodeficiency virus 
Ig  immunoglobulin 
MAp17 matrix protein p17 
mRNA  messenger RNA 
min  minute 
kan  kanamycin 
KF  Klenow fragment 
OD  optical density 
o/n  overnight 
PCR  polymerase chain reaction 
RNA  ribonucleic acid 
RIN  RNA integrity number 
S. Typhi Salmonella enterica serovar Typhi 
s  second 
scFv  single-chain fragment variable 
ssDNA single stranded DNA 
SDS  sodium dodecyl sulphate 
SDS-PAGE SDS-polyacrylamide gel electrophoresis 
xvii 
 
V-gene variable gene 
VH  variable heavy 
VL  variable light 
Ub  ubiquitin 
UV  ultraviolet 
 
  
xviii 
 
LIST OF SYMBOLS 
o
C  degree Celcius 
g  gram 
xg  gravity force 
L  liter 
μg  microgram 
μL  microliter 
mg  milligram 
mL  milliliter 
ng  nanogram 
nm  nanometer 
rpm  revolution per minute 
U  unit of enzyme 
v/v  volume / volume 
w/v  weight / volume 
 
  
xix 
 
LIST OF PUBLICATIONS 
LIM, B. N., TYE, G. J., CHOONG, Y. S., ONG, E. B. B., ISMAIL, A. & LIM, T. S. 
2014. Principles and application of antibody libraries for infectious diseases. 
Biotechnology letters, 36, 2381-2392. 
LIM, B. N., CHOONG, Y. S., ISMAIL, A., GLÖKLER, J., KONTHUR, Z. & LIM, 
T. S. 2012. Directed evolution of nucleotide-based libraries using lambda 
exonuclease. Biotechniques, 53, 357. 
 
 
  
xx 
 
 
 
 
  
xxi 
 
 
  
xxii 
 
PENJANAAN SEBUAH PERPUSTAKAAN ANTIBODI NAIF scFv 
MANUSIA BAGI MENGHASILKAN ANTIBODI MONOKLON 
MANUSIA DENGAN MENGGUNAKAN TEKNOLOGI 
PAMERAN FAJ 
 
ABSTRAK 
Perpustakaan antibodi naïf boleh mengatasi batasan kaedah tradisional 
hibridoma untuk menghasilkan antibodi monoklonal. Pendulangan pameran faj ialah 
sejenis teknik yang lebih kos efektif and menjimatkan masa untuk menghasilkan 
antibodi. Kepelbagaian perpustakaan antibodi naïf yang dibina amat penting bagi 
memastikan kejayaan dalam memperkaya antibodi terhadap pelbagai jenis sasaran 
antigen. Strategi baru untuk meningkatkan afiniti pengikatan antibodi diperkenalkan 
juga. Perpustakaan antibodi naïf scFv dibina daripada 90 orang penderma yang 
terdiri daripada kumpulan etnik yang berlainan (Melayu, Cina and India) dengan 
distribusi jantina yang sama. Semua kemungkinan V-gen antibodi diperkayakan 
dengan PCR konvensional kemudiannya diklonkan dalam vektor fajmid. Dua cara 
yang berbeza telah digunakan untuk menjana perpustakaan antibodi, iaitu 
perakitan PCR dan pengklonan dua langkah. Kedua-dua perpustakaan antibodi yang 
dibina mempunyai saiz anggaran 2x10
9
. Walau bagaimanapun, cara perakitan PCR 
menunjukkan kadar kemasukan sebanyak 67 % sahaja manakala pengklonan dua 
langkah mencapai 80 %. Perpustakaan antibodi disaring untuk mendapatkan antibodi 
monoklonal terhadap tiga jenis antigen, iaitu ubiquitin, hemolysin E dan HIV matriks 
protein p17 (MAp17). Penyaringan dijalankan dengan menggunakan dua jenis teknik, 
semi-automatik dan pendulangan konvensional. Antibodi monoklonal scFv manusia 
telah diperoleh bagi semua antigen. Penggunaan gen-V pada rantai berat dan rantai 
ringan bagi semua antibodi monoklonal telah dikaji. Rantai berat untuk antibodi 
xxiii 
 
terhadap ubiquitin dan hemolysin E adalah terdiri daripada IGHV3 manakala rantai 
berat untuk MAp17 adalah IGHV1. Sementara itu, rantai ringan untuk antigen-
antigen tersebut adalah IGKV1, IGLV2 and IGLV1 masing-masing. Aktiviti 
pengikat untuk antibodi yang diperolehi juga dinilai dalam bentuk larut. Di samping 
itu, satu teknik baru bagi meningkatkan kepelbagaian antibodi telah diperkenalkan 
dengan menggunakan exonuklease lambda untuk menghasilkan DNA untai tunggal 
(ssDNA) sebagai templat untuk tujuan mutagenesis. Dua jenis randomisasi telah 
ditunjukkan dengan menggunakan teknik ini, iaitu pangacakan rantai dan 
mutagenesis rawak CDR3. Keadaan yang terbaik untuk meghasilkan ssDNA adalah 
meggunakan 1 μg DNA dengan 10 U lambda exonuklease pada 37 oC selama 30 
mins. Kesimpulannya, kepelbagaian perpustakaan antibodi naïf scFv yang dibina 
menghasilkan antibodi monoklonal larut terhadap antigen.  
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GENERATION OF A NAÏVE HUMAN scFv ANTIBODY 
LIBRARY FOR THE PRODUCTION OF HUMAN 
MONOCLONAL ANTIBODIES BY USING PHAGE DISPLAY 
TECHNOLOGY 
 
ABSTRACT 
Naive antibody libraries are able to overcome the limitation of traditional 
hybridoma method in producing monoclonal antibodies. Phage display biopanning is 
a more cost effective and less time consuming technology for antibody production. 
Construction of a naive antibody library with a large diversity is crucial to ensure 
successful enrichment of antibodies against various target antigens. A naïve scFv 
antibody library was constructed from 90 donors of different ethnic groups (Malay, 
Chinese and Indian) with an equal gender distribution. All possible antibody V-genes 
were amplified by conventional PCR method and cloned into a phagemid vector. 
Two different approaches were used to generate the antibody library, namely PCR 
assembly and two step cloning. Both antibody libraries constructed had an estimated 
size of 2x10
9
. However, the PCR assembly method showed an insert rate of 67 % 
only while two step cloning reached 80 %. The antibody library was used to screen 
for monoclonal antibodies against three different types of antigens, ubiquitin, 
hemolysin E and HIV matrix protein p17 (MAp17). Selection of monoclonal 
antibody was carried out using two different techniques, semi-automated and 
conventional plate biopanning. Human monoclonal scFv antibody was successfully 
obtained for all the antigens. V-gene usage of heavy chain and light chain of all the 
antibody clones were studied. Heavy chain of antibody against ubiquitin and 
hemolysin E were made up from IGHV3 whereas the heavy chain for MAp17 was 
from IGHV1. Meanwhile the light chain for the antigen was from IGKV1, IGLV2 
xxv 
 
and IGLV1 respectively. The antibodies enriched were also evaluated in soluble 
form for binding activities. In addition, a novel method to increase antibody diversity 
was introduced utilizing lambda exonuclease to create single-stranded DNA (ssDNA) 
as template for mutagenesis. Two types of randomization were demonstrated using 
this method, chain shuffling and CDR3 random mutagenesis. The best condition for 
ssDNA generation was incubating 1 μg of DNA with 10 U lambda exonuclease at 37 
o
C for 30 mins. In conclusion, the diverse naïve scFv library generated was able to 
generate soluble monoclonal scFv antibodies against the target antigens. 
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CHAPTER 1 
 
INTRODUCTION 
 
1.1 Research background 
In the immune system, plasma B-cells secrete Y shape proteins known as 
antibodies to identify and remove foreign molecules from the body. Antibodies have 
been identified as the key protein in target recognition which can be exploited for 
many applications. This is because antibodies have an unique structure with good 
specificity and affinity to target antigens (Padlan, 1994). It is with this mechanism 
that antibodies are able to specifically identify target antigens and neutralize them. 
The human body is capable of producing a mixture of antibodies that is capable of 
binding to an array of different antigens. This collection of various target specific 
antibodies is called a polyclonal antibody. However, polyclonal antibodies lack in the 
specificity of a monoclonal antibody whereby it targets only a specific site on the 
target protein (Schirrmann et al., 2011).  
Monoclonal antibodies were first described by Kohler and Milstein (Köhler 
and Milstein, 1975). The conventional method to produce monoclonal antibodies is 
by using the hybridoma technique. Production of hybridomas involves the fusion 
between spleen cells of an immunized animal to myeloma cells. This will allow the 
hybridoma to present a hybrid characteristic of both the myeloma and spleen cells. 
However, since hybridoma antibodies require the use of animals as a host and host 
specific myeloma cells, this method cannot be applied for human antibody 
production.  
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Recent advancement in recombinant antibody engineering has helped resolve 
a number of challenges associated with animal derived antibodies in order to avoid 
possible cytotoxic side effects when used in humans. For instance, the introduction 
of humanized and chimeric antibodies (Smith et al., 2004). These antibodies were 
developed with both murine and human DNA sequences. The past decade has 
witnessed the introduction of antibody phage display as a new route for generating 
monoclonal antibodies. Phage display derived antibodies has become a major 
approach as it allows the antibodies selection of highly specific binders from a highly 
diverse antibody library (Boel et al., 2000).  
Furthermore, recombinant antibody technology allows customization of 
screening conditions and additional genetic manipulation for selection of high 
affinity monoclonal antibodies.  As antibodies have high specificity and affinity 
towards specific target antigens, the potential of antibodies in diagnostic and 
therapeutic applications is enormous (Dimitrov, 2010).  
 
1.2 Literature review 
1.2.1 Immune system  
The immune system is mainly involved in the defence against invading 
pathogenic organisms to the body (Boyden, 1966). The two main aims of the 
immune system that are triggered when the body encounters a pathogen is the innate 
and adaptive immunity. The innate immune system that serves as the first line of 
defence will immediately eliminate pathogens, while the adaptive immune system is 
initiated as a secondary immune response upon failure of the innate system to kill the 
pathogens. Adaptive immune system is made up of the humoral immune system (B 
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lymphocyte) and cell-mediated immune system (T lymphocyte) (McCullough and 
Summerfield, 2005). 
In the humoral immune system, B lymphocytes are responsible for the 
production of antibodies which recognize specific target antigens. Plasma B-cells 
secreting antibodies are derived from B lymphocytes. B lymphocytes develop and 
mature into plasma B-cells when activated by the binding of antigens on its surface 
through the B-cell receptor (Yancopoulos and Alt, 1986). When antibodies recognize 
target antigens, the antibody-antigen complex is formed and agglutination will take 
place. This will lead to phagocytosis by macrophages or other complement immune 
response to get rid of the pathogens. 
 
1.2.2 Antibody and its classes 
Antibodies or immunoglobulins (Ig) are globular proteins produced by B 
lymphocytes as part of the immune system. They are secreted by plasma B-cells as 
soluble protein into the cellular fluid environment where it will move in circulation 
to identify, capture and remove pathogenic proteins (Boes, 2000). 
There are five classes of heavy chains and two classes of light chains. 
Although antibodies comprise of both heavy and light chains, antibodies are 
categorized according to their heavy chain only. There are five different classes of 
antibodies, which are alpha (α), delta (δ), epsilon (ε), gamma (γ), mu (μ) 
corresponding to IgA, IgD, IgE, IgG and IgM respectively (Davies and Metzger, 
1983). Depending on the class of the antibody, the heavy chain constant region can 
be further divided to either three or four variable domains (CH1, CH2, CH3, CH4). On 
the other hand, light chains can only be grouped as either lambda (λ) or kappa (κ). 
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All classes of antibodies have different biological functions with a distinct location in 
the body.  
IgM is the first antibody to respond during initial exposure to an antigen. The 
heavy chain of the IgM monomer has one variable and four constant region domains 
without the hinge region (Figure 1.1). The hinge region is the area between the first 
and second constant region domain of the heavy chain that creates the Y shape of an 
antibody and provides antibody flexibility. The hinge region can be found in IgG, 
IgA and IgD only. Although IgM exists as a monomer, it can also form pentamers as 
well with a J chain. The J chain joins five IgM monomers together to form a 
pentameric structure and creates a total of 10 antigen binding sites (Randall et al., 
1992). The pentameric structure of IgM makes it the largest antibody with 
approximately 970kDa in size. As the result of the unique structure, IgM possesses 
higher avidity compared to other classes of antibodies. As IgM is mainly produced 
by pre-B cell that would not have had contact with a target antigen, the repertoire of 
the IgM antibodies is naive. The naive nature of the repertoire would allow for the 
generation of highly diverse antibodies against an array of target antigens making it 
ideal as the first line responder during an infection. Thus, IgM plays an important 
role to immediately eliminate antigens in the early stage of exposure. 
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Figure 1.1: Structure of an antibody molecule. The structure of immunoglobulin 
M (IgM) pentamer on left and monomer on right 
  
 
CDR: complementary determining regions 
VH: variable heavy 
VL: variable light 
CL: constant light 
Cμ: constant mu 
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1.2.3 The structure of antibody 
All antibodies have a basic Y shape structure consisting of an identical pair of 
heavy chain and light chain polypeptides. Both chains are held together by disulphide 
bonds and non-covalent bonds (Brinkmann et al., 1995).  Each heavy chain and light 
chain consists of two regions; variable region (V) and constant region (C) which 
reflects the VH and CH for the heavy chain and VL and CL for the light chain 
(Edelman, 1973). 
 Fv (fragment variable) region of an antibody is the variable region of both 
the heavy chain (VH) and light chain (VL) that creates the antigen binding site (Skerra 
and Pluckthun, 1988). Fc (fragment crystallizable) region is made up of a pair of 
heavy chain constant domains. In short, the Fv region contains the antigen binding 
site while the Fc region is responsible for the recruitment of cellular actions such as 
complement activation. 
Antibodies bind target antigens through the antigen binding site or paratope 
while the paratope recognizes the epitope of an antigen (Hoogenboom and Chames, 
2000). The antigen binding site is made up of the combination of both VH and VL. 
Each VH and VL has their own alternating conserved frameworks (FR) and diverse 
complementary determining regions (CDR) whereby three CDRs are situated in 
between four FRs. These highly diverse CDRs are crucial to generate antibody’s 
diversity.  
 
 
  
7 
 
1.2.4 Recombinant antibody 
Recombinant antibodies can be presented in several different formats  as 
shown in Figure 1.2 (Hudson, 1998, Bird et al., 1988). Fragment antibody (Fab) is a 
larger format of antibody consisting of the variable and constant region, where VH-
CH (variable heavy and constant heavy) and VL-CL (variable light and constant light) 
are linked together by an interchain disulphide bond. The disulphide bond is formed 
from the C-terminus of light chain to a cysteine peptide on the CH1 domain or hinge 
between CH1 and CH2 of heavy chain (Williams and Barclay, 1988). A smaller size 
of the recombinant form of an antibody is termed as the single-chain variable 
fragment (scFv). This format of antibody only consists of variable regions, VH and 
VL.  A short repetitive stretch of glycine and serine peptide sequence is used as a 
linker to hold both the VH and VL regions together. Depending on the length of the 
linker, scFv molecules could form dimer, trimer or even tetramers (Hudson and Kortt, 
1999). The smallest antibody fragment is single domain antibody (sdAb) or 
nanobody (Muyldermans, 2001). This format of antibody contains only the single 
variable domain either derived from the heavy chain or light chain.  
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Figure 1.2: Different formats of antibodies. Various recombinant antibody formats 
(Barthelemy et al., 2008) 
 
 
 
 
 
VL: variable light 
VH: variable heavy 
scFv: single chain fragment variable 
Fab: fragment antigen binding 
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1.2.5 Diversity of antibody 
Generally, the diversity of an antibody is created at the germline level. 
During B-cell development, a germline repertoire of no fewer than 250 gene 
segments is used to generate a much larger repertoire of variable domain structures. 
Combinatorial rearrangement of different variable (V), diversity (D) and joining (J) 
gene segment takes place in the bone marrow to produce diverse primary antibody 
repertoires (Tonegawa, 1983). The heavy chain is generated by pairing of the V, D 
and J segments while the light chain has only the V and J segments. This 
combination creates large diversities that contribute to the unique antigen binding 
site or paratope of an antibody. Furthermore, somatic hypermutation, a mechanism to 
increase antibody diversity also takes place during B-cell differentiation (Di Noia 
and Neuberger, 2007). Somatic hypermutation leads to the changes of the antibody 
gene to create further variation and increase antibody binding affinity.  
 
1.2.6 Antibody library 
The human immune system can potentially generate 10
8
-10
12
 different 
antibodies. To replicate this in vitro, a highly diverse collection of antibodies would 
be required to generate a representation of the in vivo repertoire. This is only feasible 
with the generation of diverse phage antibody library. There are three types of 
antibody libraries depending on the origin of the repertoire, which is the naïve, 
immunized and synthetic antibody library (Figure 1.3). 
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Figure 1.3: Schematic diagram of antibody library generation. Different types of 
antibody based libraries, naive, immunized and synthetic (Lim et al., 2014). The 
repertoires for naïve antibody library derived from healthy donor, the host for 
immunized antibody library had been exposed to disease and repertoires for semi-
symthetic and symthetic library are synthetically synthesis  
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1.2.6.1 Naïve library 
Naïve or non-immunised libraries can be constructed by amplifying IgM 
repertoires from B-cells of an unimmunized pool. B-cells can be harvested from the 
peripheral blood lymphocytes, bone marrow or spleen cell (Marks et al., 1991). In 
many cases, the lymphocytes can be derived from either a human or animal origin 
(Clackson et al., 1991). Several naive antibody libraries have been reported to be 
generated from human, mouse, rat, sharks and even camels. The main similarity 
between these different libraries is that the hosts or donors are healthy and are not 
infected with any diseases. The term naive reflects the nature of the antibody 
repertoire available or used. The repertoire would have to be unbiased and is diverse 
to cater for the generation of a large collection of antibodies. Naive antibody libraries 
are usually generated using the antibody repertoire from the IgM isotype. The IgM 
family has an immature repertoire that provides an unbiased characteristic which is 
ideal to create naïve repertoire (Dobson et al., 2005). This is because IgM is 
produced at the early stages of B-cell development where exposure to any foreign 
antigen has not taken place yet. It is this characteristic that makes IgM repertoires 
highly suitable for use in naive library generation. This library is very useful as large 
repertoires are available from a large collection of human V-genes and is rearranged 
in vitro to further enhance the diversity (Marks, 2003). Although the construction of 
the library is time consuming and challenging as the size of the library required must 
be large in diversity, the library is favourable solution for antibody development as it 
can be used to generate antibodies against all types of antigens. 
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1.2.6.2 Immunized library 
Immunized libraries can also be derived from both human or animal origin, 
which experienced earlier exposure to a certain disease. The size of the library can be 
smaller in comparison to naïve libraries as this type of library consists of antibodies 
that are more specific against a certain target. For humans, the V-gene used to 
construct this library is amplified from IgG repertoires from B-cells (Azzazy and 
Highsmith, 2002). The library repertoires will consist of enriched antigen-specific 
antibodies that would have undergone affinity maturation in vivo. The antibodies 
produced would generally have a higher affinity compared to naive libraries. Even so, 
a major disadvantage of immunized libraries is the constant need to create a new 
library for every new antigen as the repertoire is biased towards a certain disease or 
infection (Hoogenboom, 1997). This is not efficient in terms of time and cost for 
general antibody production processes.  
 
1.2.6.3 Synthetic library 
This type of library is constructed in vitro based on a fully synthetic construct. 
The construction of a synthetic library is generally made up of randomized sequences 
in the antibody binding site of a fixed selected framework. A synthetic repertoire can 
be generated easily with the advancements of bioinformatic to identify stable and 
suitable antibody structures (Ponomarenko et al., 2008). Synthetic antibodies are 
made up of a fixed framework, generally the most stable ones and the diversity is 
introduced by synthetic oligonucleotides (Sidhu and Fellouse, 2006). The diversity 
generated by synthetic libraries is rather similar to that of naive libraries. This is 
because there is no preference in the repertoire as the diversity is generated randomly 
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mainly by combinatorial mixing. In vivo, antibody CDR segments show high 
variation not only in terms of amino acid propensities but also in terms of length. The 
variation of lengths in synthetic libraries is very challenging as opposed to a natural 
naive library. In certain instances, the use of fixed framework sequences and CDR 
randomization could be detrimental to the library quality as the diversity could be 
reduced in this manner. However, the process to create highly diverse synthetic 
libraries is possible with various advancements in molecular based methods. The 
HuCAL library is a good example of such a diverse library but the eventual cost to 
generate such a library is high and mostly unaffordable by most laboratories 
(Knappik et al., 2000).  Therefore, naive antibody libraries are still the preferred 
choice for an all rounded antibody library. 
 
1.2.7 Phage display  
Phage display is a technology which was first described by George P. Smith 
demonstrating presentation of peptides as a fusion with the pIII protein of 
filamentous phage (Smith, 1985). Using phage as a host, a repertoire of random 
peptides can be expressed on its surface allowing a physical interaction between the 
phenotype and genotype. The phage presenting peptides can then be used for 
screening or selection to identify interaction partners. Phage display is proven to be a 
very powerful technique to display libraries containing millions or even billions of 
different peptides or proteins with their functionality still intact (Paschke, 2006). 
Phage display system is becoming a popular approach used to create possible binders 
against any target rapidly by in vitro selection. Several applications of phage display 
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includes antibody generation, enzyme evolution and interaction partner identification 
(Li and Caberoy, 2010, Pansri et al., 2009). 
 
1.2.7.1 Phage biology 
There are many different types of bacteriophage being used but filamentous 
phage is most commonly used for phage display. The filamentous phage particles 
mostly used for phage display is M13 which is a non-lytic filamentous phage (Barbas 
and Barbas, 1994). M13 infects E. coli containing the F pilus, for instance XL1 blue, 
TG1 and ER 2738 bacteria strains.   
M13 phage contains a single stranded DNA genome with 6407 nucleotides 
coding 11 proteins. p1, p4 and p11 are involved in phage assembly and exportation. 
p2, p5 and p10 are important for DNA replication while p3, p6, p7, p8 and p9 make 
up the five types of  phage coat proteins needed for phage packaging (Lopez and 
Webster, 1983). The major coat protein of a phage particle is p8 displaying up to 
2700 copies. p7 and p9 each has 5 copies of protein as phage head protein while p3 
and  p6 make up the phage tail protein with each having 5 copies of proteins as well. 
In most phage display applications, either p3 or p8 are used for displaying peptide or 
protein (Rodi and Makowski, 1999).  
Life cycle of M13 phage can be divided into three stages; attachment, DNA 
replication and exportation. Infection starts when p3 of M13 phage attaches to the F 
pilus of E. coli.  Then, single-stranded DNA of M13 enters the bacteria and converts 
into the replicative form. Using the replicative form as template, DNA is replicated 
by rolling circle replication mechanism. Then, phage particles are assembled and 
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extruded out bacterial membrane without cell lysis (Marvin, 1998, Ebrahimizadeh 
and Rajabibazl, 2014). 
The P3 is made up of two domains, the N1 and N2 domains. During infection, 
domain N2 will attach itself to the F pilus of the bacterial cell. Contraction of the F 
pilus will allow the N1 domain to bind to the TolA protein on the bacterial cell 
membrane. This will facilitate the entry of the phage DNA into the bacterial 
cytoplasm. Phage single-stranded DNA will first be converted into its replicative 
form by host polymerases and enzymes. This replicative form acts as template for 
phage gene expression and replication. Phage single-stranded DNA is then replicated 
using rolling circle amplification technique while phage coat proteins are expressed. 
Phage coat proteins will assemble at the cytoplasmic membrane when phage single-
stranded DNA is ready. Finally, new phage particle is packaged and secreted from 
the bacterial cell without cell lysis (Russel, 1993, Rakonjac and Model, 1998).  
 
1.2.7.2 Antibody phage display 
The antibody genes encoded in the phage allows for the gene products to be 
displayed on the surface of filamentous phage as fusion proteins. This collection of 
phage is called a phage display antibody library, where each phage particle displays a 
single unique antibody in accordance to the antibody genotype encoded by the phage 
particle (Winter et al., 1994). In order to construct an antibody phage library, 
antibody genes are fused to phage genes mainly gIII, thus creating a link between 
antibody phenotype and its encoded genotype (Barbas et al., 1991) (Figure 1. 4). So, 
it is easier for target antibody enrichment, duplication and identification after 
selection. 
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Due to the difficulty in assembling and displaying a complete antibody 
fragment that has a large molecular size around 150 kDa on the phage surface, 
smaller antibody fragments are normally preferred. Both scFv (25-30 kDa) and Fab 
(~60 kDa) formats have been used successfully in constructing phage antibody 
library. scFv is small in size and has huge advantages for display as it is easier to 
present with a better production rate as a fusion protein in an E. coli cell. A potential 
problem with such fragments is the ability to form multimers which may disrupt 
binding by steric hindrance (Kortt et al., 1997). On the other hand, Fab is more stable 
since it consists of constant domains and disulphide bonds to hold the molecule 
together. Fab is normally chosen over the scFv format when a complete antibody 
structure is needed as the final product (Feldhaus et al., 2003). This is because 
removal of the scFv linker might result in the change of antigen binding properties. 
The choice of whether to produce scFv or Fab antibody library would mainly depend 
on downstream applications (Carmen and Jermutus, 2002).  
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Figure 1.4: Structure of phage particle. Phage particle has five major coat proteins 
(p3, p6, p7, p8 and p9). Phage particle displayed scFv antibody fragment at p3 
  
p3: protein 3 
p6: protein 6 
p7: protein 7 
p8: protein 8 
p9: protein 9 
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1.2.8 Biopanning  
Biopanning is a process in phage display where unique phage clones that bind 
to the target of interest are identified (Willats, 2002). This process usually involves 
consecutive rounds of binding, washing, elution and amplification. After several 
rounds of biopanning, affinity selection of the libraries will result in the enrichment 
of only antigen bound phages (Figure 1.5). 
In the binding step, the antibody phage library is incubated with the 
immobilized target antigen to screen for possible antibody displaying phage. Target 
antigen is first immobilized on a solid phase, for instance immunotube, polysterene 
microplate and magnetic nanoparticle (Steiniger et al., 2007, Konthur et al., 2010). 
Target phage is captured during incubation through affinity binding. After the 
binding step, the wash step is carried out so that unbound phages will be washed 
away. Washing is very important to wash off phage that binds non-specifically to the 
surface of the solid support. To ensure strong binders are obtained, more washing 
steps and stringency in washing condition are introduced. After washing, only phage 
displaying antibody that bind specifically to the antigen is remained. This phage 
particle is then eluted. Elution of bound phage can be done by changing pH or using 
enzymatic cleavage (D’Mello and Howard, 2001, Corey et al., 1993). Lastly, eluted 
phages are amplified in E. coli for subsequent round of panning. Phages with higher 
affinity and specificity are enriched at the end of the selection round. 
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Figure 1.5: Schematic diagram of biopanning. Biopanning is a process involves 
four consecutive rounds of binding, washing, elution and amplification steps to 
enrich unique antibody clone through affinity selection  
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1.2.9 Antibody mutagenesis 
Panning of phage displayed antibody is targeted to isolate antibody with high 
specificity and affinity. However, antibodies selected from naïve antibody library 
generally have relatively low affinities. Antibodies with low affinity may suffer from 
certain limitations in terms of binding capacity and specificity in diagnostic or 
therapeutic application. To overcome this, in vitro affinity maturation can be done to 
improve antibody binding affinity (Wang et al., 2006). Various methods have been 
developed to increase antibody affinity through mutagenesis such as chain shuffling 
and CDR mutagenesis (Lou and Marks, 2010, Drummond et al., 2005) (Figure 1.6). 
In general, the heavy chain and light chain of an antibody determine its 
binding affinity and specificity. By shuffling between heavy and light chains or 
making new chain combinations, the affinity and specificity of the antibody can be 
altered (Christensen et al., 2009). Through in vitro affinity maturation, new chain 
combinations are useful to generate higher antibody affinity. CDR region of the 
antibody creates the binding site for antigen capture. The binding site is formed by a 
total of six CDRs, three CDRs each in the heavy chain and light chain respectively. 
Mutations on CDRs can change the structure of the antigen-binding site thus 
modifying the antibody affinity as well (De Kruif et al., 1995). The most significant 
affinity changes often result from mutations in the CDR3 of the heavy chain (Xu and 
Davis, 2000). Therefore a directed process for affinity modification is a critical step 
in the production and improvement of antibodies for downstream applications. 
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Figure 1.6: Methods of antibody mutagenesis. Two different strategies for 
antibody mutagenesis to increase antibody diversity (Lim et al., 2014), shuffling 
between heavy chain and light chain and randomization in CDR region 
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1.3 Rationale of study 
The generation of monoclonal antibodies has traditionally involve the use of 
the hybridoma method. However, conventional hybridoma technique has several 
limitations and requires tedious animal immunisation for each desired antigen targets 
A more cost effective alternative for antibody production would be beneficial for 
long term applications. Phage display offers the possibility of producing recombinant 
antibodies at any given time with the generation of a naive antibody library. The 
method has been proven to be a rapid and robust method to generate antibodies 
against various antigens. By using phage display, selection of novel antibodies that 
bind against various types of antigens especially pathogen targets is feasible at a 
faster and more cost effective rate. Thus, the use of antibody phage display to 
identify specific antibodies for diagnostic and therapeutic applications has been 
widely exploited. 
The success of any antibody library is largely dependent on the diversity of 
the repertoire generated. As genetic diversification and immune tolerance plays a 
large role in antibody diversity, the ability to generate a large and diverse library 
would require a large collection pool as well as genetically diverse backgrounds. To 
this extent the ability to collect samples from healthy donors of different ethnicity 
would provide the necessary repertoire needed for a diverse library. A naïve library 
would greatly benefit from this as the combinatorial mixing of antibody genes 
derived from different ethnic background would produce a higher diversity for a 
better quality library. 
In order to evaluate the diversity of a naïve library, the application of a single 
target antigen would not suffice. Theoretical diversity stipulates the possibility of 
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enriching antibodies against a variety of antigens with the increased diversity. 
Therefore three different antigens from different categories including human, 
bacteria and viruses were investigated. The antigens are ubiquitin, Salmonella 
enterica serovar Typhi hemolysin E protein and HIV matrix protein p17. 
Ubiquitin is a small regulatory protein with only 76 amino acids that is highly 
conserved in all eukaryotes. Ubiquitin functions by tagging to specific proteins for 
degradation. In regulatory systems, proteasome will recognize the ubiquitin tagged 
protein and proceed for degradation. As this protein is commonly found in 
eukaryotes, it appears as a good candidate to use for antibody library validation. 
Typhoid fever is a life-threatening disease caused by bacteria infection of Salmonella 
enterica serovar Typhi (S. Typhi). S. Typhi is a human pathogen producing pore-
forming toxin, hemolysin E (hlyE). HlyE is also known as cytolysin A (ClyA) and 
silent hemolysin, locus A (SheA). During infection, S. Typhi releases hlyE leading to 
haemolysis by lysing erythrocytes. Since hlyE is reported to be antigenic, it is a 
promising target for diagnostic and therapeutic. HIV gag gene produces three types 
of polyprotein, matrix protein (p17), capsid domain (p24) and nucleocapsid domain 
(p15). Matrix protein (MA) p17 is a structural protein that plays an important part in 
the early and late stages of the HIV life cycle. MAp17 is involve in the pathogenesis 
of HIV disease during virus infection and replication. Thus, MAp17 is an attractive 
target for antibody recognition as a potential solution to combat the disease. 
Antibodies with high specificity and affinity are necessary for diagnostic and 
therapeutic applications. However, antibodies obtained from phage antibody library 
may not necessary produce antibodies with high affinity. Therefore affinity 
maturation processes are also required to improve antibody quality much like the 
process that occurs naturally. Recent advancements in molecular biology methods 
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have made in vitro antibody affinity maturation faster and easier. Through affinity 
maturation, antibody binding efficiencies can be modified. The general strategy 
involving antibody maturation can be accomplished either by CDR mutagenesis of 
chain shuffling. A novel strategy for affinity maturation that would allow for rapid 
CDR mutagenesis and chain shuffling is crucial to fine tune antibody affinities after 
identification. Coupled together with a naive antibody library, a one-stop solution for 
antibody generation and modification would then be possible. 
In order to generate antibodies applicable for diagnostic applications, the 
generation of a naive antibody library is crucial. This is because the naive nature of 
the repertoire would allow the use of the library for many different antigens. As such, 
the development of a naive antibody library with a novel method for mutagenesis is 
critical in the process of generating recombinant antibodies for diagnostic 
applications.  
 
1.4 Objectives 
The main objectives of this project were as follows: 
i. To generate a naïve human scFv antibody library by using phage display 
technology 
ii. To select phage displayed monoclonal antibodies against ubiquitin, HIV 
matrix protein p17 and Salmonella Typhi hemolysin E  
iii. To produce soluble single chain fragment variable (scFv) against antigens 
iv. To develop a novel mutagenesis method for antibody maturation 
 
  
